ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

The FDA granted regenerative medicine advanced therapy designation to ATSN-201, a gene therapy candidate for the treatment of ...

Retinal pigment epithelial detachment is associated with neovascular age-related macular degeneration in 30% to 80% of cases, according to the literature.It is often difficult to treat, requires a ...